Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: Findings from the scleroderma lung study

Chest

Volumn 136, Issue 5, 2009, Pages 1333-1340

  Goldin, Jonathan ^a   Elashoff, Robert ^a   Kim, Hyun J ^a   Yan, Xaiohong ^a   Lynch, David ^c   Strollo, Diane ^d   Roth, Michael D ^a   Clements, Philip ^a   Furst, Daniel E ^a   Khanna, Dinesh ^a   Vasunilashorn, Srainnapha ^a   Li, Gang ^b   Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CYST; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCLERODERMA; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

EID: 70449434980     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0108     Document Type: Article

References (32)

1. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283-1289 (Pubitemid 24320744)
2. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-2444
3. Medsger TA Jr. Classification, prognosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004; 17-28
4. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15:748-755 (Pubitemid 38156302)
5. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666 (Pubitemid 43920839)
6. Hoyles RK, Ellis RW, Wellsbury J, et al. Fibrosing Alveolitis in Scleroderma Trial (FAST): a multi-centre, prospective, randomized, double-blind, placebo-controlled trial of treatment with corticosteroids and intravenous cyclophosphamide followed by oral azathioprine. Arthritis Rheum 2006; 54: 3962-3970 (Pubitemid 44955900)
7. Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35:1064-1072 (Pubitemid 351813153)
8. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838-844
9. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37:729-735 (Pubitemid 24145078)
10. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954 (Pubitemid 30397594)
11. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026-1034 (Pubitemid 350127847)
12. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease [editorial]. N Engl J Med 2006; 354:2707-2709 (Pubitemid 43920846)
13. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60:281-283 (Pubitemid 32260614)
14. Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:121-127 (Pubitemid 34685911)
15. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586 (Pubitemid 34693935)
16. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232:560-567 (Pubitemid 38971300)
17. Goldin JG, Lynch DA, Strollo DC, et al. High resolution CT findings in scleroderma-related lung diseases: findings from Scleroderma Lung Study. Chest 2008; 134:358-367
18. Wells AU, Rubens MB, du Bois RM, et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 1993; 161:1159-1165 (Pubitemid 24008055)
19. Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford) 2008; 47(suppl), v59-v61
20. Goh NSL, Desai SR, Veerarhagavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248-1254
21. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29:731-736 (Pubitemid 34303867)
22. Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29:2371-2378 (Pubitemid 35266028)
23. Pakas I, Ioannidis JPA, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29:298-304 (Pubitemid 34118777)
24. Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18:455-461 (Pubitemid 30014164)
25. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758
26. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91-98
27. BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am Rev Respir Dis 1990; 141:S169-S202
28. Altman DG, ed. Practical statistics for medical research. London, UK: Chapman and Hall, 1991; 404
29. Webb WR, Muller NL, Naidich DP. High-resolution CT of the lung. Philadelphia, PA: Lippincott Williams & Wilkins, 2000
30. Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188:499-506 (Pubitemid 23216278)
31. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88:470-476 (Pubitemid 20168722)
32. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008; 15:1004-1016 (Pubitemid 351938744)